Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Sökning: LAR1:gu > Tidskriftsartikel > Refereegranskat > Sjöström Lars > Effects of rimonaba...

Després, Jean-Pierre (författare)

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.

Artikel/kapitelEngelska2005

Förlag, utgivningsår, omfång ...

2005

Nummerbeteckningar

LIBRIS-ID:oai:gup.ub.gu.se/55464
https://gup.ub.gu.se/publication/55464URI
https://doi.org/10.1056/NEJMoa044537DOI

Kompletterande språkuppgifter

Språk:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. METHODS: We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 months in addition to a hypocaloric diet. RESULTS: The rates of completion of the study were 62.6 percent, 60.3 percent, and 63.9 percent in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, respectively. The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea. As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P<0.001) mean weight loss (repeated-measures method, -6.7+/-0.5 kg, and last-observation-carried-forward analyses, -5.4+/-0.4 kg), reduction in waist circumference (repeated-measures method, -5.8+/-0.5 cm, and last-observation-carried-forward analyses, -4.7+/-0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0+/-1.6 percent, and last-observation-carried-forward analyses, +8.1+/-1.5 percent), and reduction in triglycerides (repeated-measures method, -13.0+/-3.5 percent, and last-observation-carried-forward analyses, -12.4+/-3.2 percent). Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone. CONCLUSIONS: Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.

Ämnesord och genrebeteckningar

Adiponectin
blood
Adult
Aged
Anti-Obesity Agents
adverse effects
therapeutic use
Blood Glucose
drug effects
Cholesterol
blood
Double-Blind Method
Dyslipidemias
blood
complications
drug therapy
Female
Humans
Insulin
blood
Leptin
blood
Male
Metabolic Syndrome X
complications
Middle Aged
Obesity
blood
complications
drug therapy
Overweight
Piperidines
adverse effects
therapeutic use
Pyrazoles
adverse effects
therapeutic use
Receptors
Cannabinoid
antagonists & inhibitors
Risk Factors
Triglycerides
blood
Weight Loss
drug effects

Biuppslag (personer, institutioner, konferenser, titlar ...)

Golay, Alain (författare)
Sjöström, LarsGothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism,Institute of Internal Medicine, Dept of Body Composition and Metabolism(Swepub:gu)xsjosl (författare)
Göteborgs universitetInstitutionen för invärtesmedicin, Avdelningen för kroppssammansättning och metabolism (creator_code:org_t)

Sammanhörande titlar

Ingår i:The New England journal of medicine353:20, s. 2121-341533-4406

Internetlänk

Hitta via bibliotek

The New England journal of medicine (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Després, Jean-Pi ...; Golay, Alain; Sjöström, Lars

Artiklar i publikationen: The New England ...

Av lärosätet: Göteborgs universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se